ATE550355T1 - Antikörper gegen ccr5 und ihre verwendung - Google Patents

Antikörper gegen ccr5 und ihre verwendung

Info

Publication number
ATE550355T1
ATE550355T1 AT07818397T AT07818397T ATE550355T1 AT E550355 T1 ATE550355 T1 AT E550355T1 AT 07818397 T AT07818397 T AT 07818397T AT 07818397 T AT07818397 T AT 07818397T AT E550355 T1 ATE550355 T1 AT E550355T1
Authority
AT
Austria
Prior art keywords
ccr5
antibodies
Prior art date
Application number
AT07818397T
Other languages
English (en)
Inventor
Johannes Auer
Monika Baehner
Michael Brandt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE550355T1 publication Critical patent/ATE550355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07818397T 2006-09-29 2007-09-25 Antikörper gegen ccr5 und ihre verwendung ATE550355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06020646 2006-09-29
PCT/EP2007/008312 WO2008037419A1 (en) 2006-09-29 2007-09-25 Antibodies against ccr5 and uses thereof

Publications (1)

Publication Number Publication Date
ATE550355T1 true ATE550355T1 (de) 2012-04-15

Family

ID=37719169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07818397T ATE550355T1 (de) 2006-09-29 2007-09-25 Antikörper gegen ccr5 und ihre verwendung

Country Status (16)

Country Link
US (1) US20090110686A1 (de)
EP (1) EP2074147B1 (de)
JP (1) JP4960459B2 (de)
KR (1) KR20090052358A (de)
CN (1) CN101516914A (de)
AR (1) AR063026A1 (de)
AT (1) ATE550355T1 (de)
AU (1) AU2007302294A1 (de)
BR (1) BRPI0717512A2 (de)
CA (1) CA2664752A1 (de)
CL (1) CL2007002767A1 (de)
IL (1) IL196861A0 (de)
MX (1) MX2009002694A (de)
PE (1) PE20080971A1 (de)
TW (1) TW200821330A (de)
WO (1) WO2008037419A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918451A (zh) * 2008-01-15 2010-12-15 弗·哈夫曼-拉罗切有限公司 抗CCR5的afucosylated抗体及其用途
US20110318360A1 (en) * 2008-09-05 2011-12-29 Duke University Anti-lipid antibodies
EP2246364A1 (de) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
SG11201404263TA (en) * 2012-01-27 2014-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MY198562A (en) * 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6610834B1 (en) 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030099645A1 (en) 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
AU773175B2 (en) 1998-12-16 2004-05-20 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
JP2002540771A (ja) 1999-03-11 2002-12-03 マック，マティーアス 抗体構築物およびケモカイン構築物ならびに自己免疫疾患の治療におけるそれらの使用
WO2001042308A2 (en) 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
WO2001043779A2 (en) 1999-12-16 2001-06-21 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
CA2399593A1 (en) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US20040043033A1 (en) 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20030165988A1 (en) 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20020147147A1 (en) 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
EP1207202A1 (de) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nukleinsäuremoleküle, welche für ein Protein kodieren, das mit dem Chemokinrezeptor oder anderen Mitgliedern der Chemokinrezeptorfamilie interagiert
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CN1780907B (zh) 2002-02-22 2011-06-15 原基因药物有限公司 抗ccr5抗体
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof

Also Published As

Publication number Publication date
IL196861A0 (en) 2011-08-01
BRPI0717512A2 (pt) 2013-11-19
EP2074147B1 (de) 2012-03-21
WO2008037419A1 (en) 2008-04-03
CL2007002767A1 (es) 2008-05-30
MX2009002694A (es) 2009-03-24
AU2007302294A1 (en) 2008-04-03
TW200821330A (en) 2008-05-16
PE20080971A1 (es) 2008-07-19
AR063026A1 (es) 2008-12-23
CA2664752A1 (en) 2008-04-03
CN101516914A (zh) 2009-08-26
JP2010504739A (ja) 2010-02-18
KR20090052358A (ko) 2009-05-25
EP2074147A1 (de) 2009-07-01
JP4960459B2 (ja) 2012-06-27
US20090110686A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE550355T1 (de) Antikörper gegen ccr5 und ihre verwendung
LTPA2020540I1 (lt) Antikūnai Xa veiksnio inhibitoriams ir jų naudojimo būdai
ATE538137T1 (de) Antikörper gegen menschliches il-22 und verwendungen davon
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE548355T1 (de) 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
EP2182969A4 (de) miRNA-FAMILIE ALS FIBROSEMODULATOR UND IHRE VERWENDUNG
ATE513855T1 (de) Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür
EP2268813A4 (de) Rna-moleküle und ihre verwendung
ATE530578T1 (de) Antikörper gegen il-17a
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
EP2060040A4 (de) Verwendung von satztokens in transaktionen
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
EP2122054A4 (de) Vliestafel und konstruktionsverfahren dafür
DE602007010795D1 (de) Blattsauger und -häcksler
ATE546433T1 (de) Quinolinderivate und ihre verwendung als fungizide
EP2048195A4 (de) Anorganisch-organische hybridzusammensetzung und verwendung davon
EP1991709A4 (de) Pseudoinfektiöses flavivirus und verwendung
DE602007013869D1 (de) Substituierte imidazole und ihre verwendung als pestizide
ATE547002T1 (de) Pestizide und ihre verwendung
EP2151440A4 (de) Heterocyclische verbindung und ihre verwendung
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE502007001209D1 (de) Wachszusammensetzung und deren Verwendung
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE544752T1 (de) Aryloxyacetamidderivate und ihre verwendung als fungizide